Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities

Journal of Clinical Pharmacology

Volumn 46, Issue 2, 2006, Pages 235-243

  Tan, Keith ^a   Brayshaw, Nigel ^a   Tomaszewski, Konrad ^a   Troke, Peter ^a   Wood, Nolan ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Liver function test; Plasma concentration; Visual adverse event; Voriconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIFUNGAL AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; VORICONAZOLE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; BILIRUBIN BLOOD LEVEL; BLURRED VISION; CANDIDIASIS; CHILD; COLOR VISION DEFECT; DRUG BLOOD LEVEL; DRUG SAFETY; ESOPHAGUS CANDIDIASIS; EYE TOXICITY; FEMALE; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PHOTOPHOBIA; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK; STATISTICAL MODEL; VISION; VISUAL IMPAIRMENT;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANTIFUNGAL AGENTS; ASPARTATE AMINOTRANSFERASES; COHORT STUDIES; FEMALE; HEPATITIS, TOXIC; HUMANS; LIVER FUNCTION TESTS; MALE; PYRIMIDINES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; TRIAZOLES; VISION DISORDERS;

EID: 31344478761     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270005283837     Document Type: Article

References (25)

1. Ghannoum MA, Kuhn DM. Voriconazole: better chances for patients with invasive mycoses. Eur J Med Res. 2002;7:242-256.
2. VFEND: Summary of Product Characteristics. Surrey, UK: Pfizer Ltd; 2002.
3. Vfend [package insert]. New York, NY: Pfizer Inc; 2003.
4. Ally D, Schürmann W, Kreisel G, et al. A randomized double blind, double dummy multicenter trial of voriconazole and fluconazole in the treatment of oesophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2002;33:1447-1455.
5. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
6. Perfect J, Marr K, Walsh T, et al. Voriconazole treatment for less common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122-1131.
7. Lazarus HM, Blumer JL, Yanovich S, et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol. 2002;42:395-402.
8. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225-234.
9. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340:764-771.
10. Boucher HW, Groll AH, Chiou CC, et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004;64:1997-2020.
11. Tomaszewski K, Purkins L. Visual effects with voriconazole [abstract] . In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, December 16-19, 2001. Washington, DC: American Society for Microbiology; 2001:A-639.
12. Tomaszewski K, Laites A, Goodrich J. The long-term visual safety of voriconazole [abstract]. Clin Microbiol Infect. 2005;11(S2):347-348. Abstract P1109.
13. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46:2546-2553.
14. Antiviral Drugs Advisory Committee. Briefing document for voriconazole. 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/ 01/briefing/ 3792b2_01_Pfizer.pdf. Accessed May 20, 2005.
15. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563-571.
16. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis. 2002;35:1273-1275.
17. Lutsar I, Hodges MR, Tomaszewski T, et al. Safety of voriconazole and dose individualization. Clin Infect Dis. 2003;36:1087-1088.
18. Purkins L, Wood N, Greenhalgh K, et al. The pharmacokinetics and safety of intravenous voriconazole: a novel wide-spectrum antifungal agent. Br J Clin Pharmacol. 2003;56(S1):2-9.
19. Purkins L, Wood N, Greenhalgh K, et al. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol. 2003;56(S1):10-16.
20. Stopher DA, Gage R. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J Chromatogr B Biomed Sci Appl. 1997;691:441-448.
21. Altman DG. Practical Statistics for Medical Research. New York, NY: Chapman and Hall; 1991:409-418.
22. Hanley JA, McNeil BJ. The meaning and use of the area under the receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
23. Liang KY, Zeger SL. Longitudinal data analysis using generalised linear models. Biometrika. 1986;73:13-22.
24. Bohme A, Karthaus M. Treatment of systemic fungal infections in patients with hematologic malignancies. Antibiot Chemother. 2000;50:79-93.
25. Min DI, Perry PJ, Chen HY, et al. Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation. Pharmacotherapy. 1998;18:282-287.